Posting $162 million in fourth-quarter net sales, a 48% increase, and $508 million for the whole yeara 50% riseOpzelura ...

Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D ...

pointing to the company's early-stage mutant CALR antibody and JAK2V617F inhibitor. Depending on phase 1 readouts for those candidates, Incyte will have the luxury of deciding whether it makes ...

Human basophils, first identified over 140 years ago, account for just 0.5-1% of circulating leukocytes. While this scarcity long hampered basophil studies, innovations during the past 30 years, ...

• Heat-inactivated E. coli-elicited acute infection triggers expansion of lineage − sca-1 + c-kit + (LSK) cells. • HIEC-elicited acute infection reduces the frequency of functional HSCs in expanded ...

Source: Getty Images Primary myelofibrosis is a rare cancer. In the United States (US), the annual incidence is approximately 0.3 cases per 100,000 individuals. The median age of patients with ...

ABSTRACT Introduction: The treatment of elderly multiple myeloma (MM) patients with autologous stem cell transplantation (ASCT) is a controversial procedure. Most clinical trials evaluating the safety ...

The central role of the control of apoptosis in the pathophysiology of Philadelphia chromosome-negative myeloproliferative neoplasms has recently been reinforced in genetic and pharmacological studies ...

Consistent with these findings, CK2 inhibitors have recently been shown to suppress the constitutive autophosphorylation of mutated JAK2V617F and induce apoptosis in cells from patients with ...